News | December 27, 2022
Hetero's COVID-19 oral drug gets WHO prequalification
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Sputnik Light is the first component of Sputnik V
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)